FLT3 and acute myeloid leukemia: The use of a kinase inhibitor, midostaurin, as an adjunct to conventional therapy, daunorubicin and cytarabine (induction therapy), and then to high doses of cytarabine (consolidation therapy) also promoted an increase in overall and event-free survival in AML patients with FLT3 mutation, and, more precisely, increased the 4-year OS from 44.3% to 51.4% [63].